GANTRISIN
LOE ApproachingNDAORALSYRUP
Approved
Dec 1953
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 2d ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
GANTRISIN is an oral syrup antibiotic approved in 1953 by Roche, representing a legacy small-molecule antimicrobial. The drug's exact indications and mechanism are not currently documented in available data. Historical use included treatment of bacterial infections, though current therapeutic positioning requires verification.
LOE Approaching
As a legacy product approaching loss of exclusivity with low current competitive pressure (30), team size is likely minimal and focused on managed decline rather than expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
With zero linked job openings and an approaching LOE, GANTRISIN offers limited career growth opportunity or visibility. Roles on this product are typically small, focused on defending market share and managing regulatory compliance in a declining franchise.
Brand ManagerProduct Manager
Worked on GANTRISIN at Roche? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.